ARA-290 vs Vladonix

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.

Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocyte populations. As a thymic tissue-derived bioregulator, Vladonix shares its mechanistic framework with thymalin, the better-characterized Khavinson thymus compound; both are proposed to interact with chromatin regulatory elements in thymic cells to reactivate gene expression programs that decline with immunosenescence, potentially restoring T-cell maturation and peripheral immune competence. Published research from the Khavinson group on thymus-derived short peptides, including thymalin, has demonstrated human hematopoietic stem cell differentiation activity, immune modulation in aged subjects, and class-level evidence for thymic peptide bioregulation, providing biological plausibility for this compound class. Vladonix has no FDA approval and no approved indication in any Western jurisdiction; it is the commercial thymic bioregulator product distinct from thymalin but sharing the same class evidence framework, with no independent published clinical trials specific to this formulation, and its use is confined to the Russian integrative and anti-aging medicine context.